Tech Company Financing Transactions
Chrysalis BioTherapeutics Funding Round
Chrysalis BioTherapeutics, based in Galveston, received $10.4 million from Biomedical Advanced Research and Development Authority.
Transaction Overview
Company Name
Announced On
12/2/2020
Transaction Type
Venture Equity
Amount
$10,400,000
Round
Undisclosed
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2200 Market St. 609
Galveston, TX 77550
USA
Galveston, TX 77550
USA
Phone
Website
Email Address
Overview
ChrysalisBioTherapeutics, Inc. is a clinical stage biopharmaceutical company developing regenerative drugs that mimic the body's natural signals to activate endothelial cells and stem cells to stimulate tissue repair and restore normal tissue function.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Darrell Carney
Chief Financial Officer
Clarice Motter
Executive Vice President
Laurie Sower
VP - R & D
Gerald Fuller
Browse more venture capital transactions:
Prev: 12/2/2020: Fakespot venture capital transaction
Next: 12/2/2020: Click Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs